Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
CAI Stock Chart & Stats
$18.56
--
Market closed
$18.56
--
Day’s Range― - ―
52-Week Range$17.15 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.56M
Market Cap
$5.18B
Enterprise Value$4.76B
Total Cash (Recent Filing)$800.09M
Total Debt (Recent Filing)$378.99M
Price to Earnings (P/E)―
Beta1.80
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.28
Shares Outstanding282,579,930
10 Day Avg. Volume3,148,629
30 Day Avg. Volume2,557,481
Financial Highlights & Ratios
PEG Ratio2.83
Price to Book (P/B)78.14
Price to Sales (P/S)55.55
P/FCF Ratio674.37
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.86
Enterprise Value/Gross Profit8.83
Enterprise Value/Ebitda1.13K
Forecast
1Y Price Target
$33.11Price Target Upside78.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.18
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Guidance And Cash GenerationManagement's revenue guidance above consensus and the stated objective of achieving adjusted profitability and positive cash flow while scaling the commercial team supports confidence in future cash generation.
Pipeline And Commercial PartnershipsEncouraging interim data for multi-cancer early detection programs and a commercialization partnership for a blood-based screening test create a potential new revenue avenue beyond core molecular profiling.
Revenue Growth And VolumesStrong increases in clinical case volumes for both tissue and blood testing, paired with high gross margins, can sustain revenue growth and lift overall operating performance.
Bears Say
Accounting And Earnings QualityPortions of reported revenue growth were driven by accounting true-ups from prior periods, which may overstate underlying operational momentum and complicate earnings comparisons.
Cost Expansion And Margin PressurePlanned expansion of the commercial salesforce will increase operating expenses and could pressure short-term margins and profitability as new hires ramp up.
Valuation And Price Target RiskAnalyst-led price target reductions and expectations of valuation multiple compression in the diagnostics sector reduce clarity on upside potential and raise valuation risk.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $17.15 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $5.18B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 144 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Feb 26, 2026. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.049 by $0.231.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,579,930 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0.28 in its last earnings report, beating expectations of $0.049. Following the earnings report the stock price went up 4.678%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.11 (78.39% Upside)
$33.11 (78.39% Upside)
Blogger Sentiment
Neutral
CAI Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 5.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Fundamentals
Return on Equity
24.96%
Trailing 12-Months
Asset Growth
227.48%
Trailing 12-Months
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial momentum: very high revenue growth, substantial margin expansion, multiple quarters of positive adjusted EBITDA and free cash flow, a large and growing genomic data asset, and encouraging interim MCED (Caris Detect) results (AUC 0.90, Stage I/II sensitivity 63.1%). Management outlined committed reinvestment in commercial expansion, R&D and MCED capacity while maintaining positive cash flow. Key risks and near-term uncertainties include the interim nature of MCED data (blinded validation and ACHIEVE-2 pending), reimbursement and ASP variability, a meaningful increase in OpEx and CapEx for 2026, and uneven pharma revenue cadence. On balance, the positive financial performance, strong cash position and promising product pipeline outweigh the listed risks.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$33.11
▲(78.39% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---